Skip to content
10-Q

Quarterly Report

Adaptive Biotechnologies Corp ADPT

0000950170-24-123423

← back to feed
Filed
Nov 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 4, 2024 147.58M sh
Long Term Debt Q3 2024 · Sep 30, 2024 $132.7M
Long Term Debt Q3 2024 · Dec 31, 2023 $130.66M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $38.08M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $65.06M
Stockholders Equity Q3 2024 · Sep 30, 2024 $223.77M
Stockholders Equity Q3 2024 · Dec 31, 2023 $308.4M
Current Liabilities Q3 2024 · Sep 30, 2024 $87.63M
Current Liabilities Q3 2024 · Dec 31, 2023 $88.02M
Total Liabilities Q3 2024 · Sep 30, 2024 $334.93M
Total Liabilities Q3 2024 · Dec 31, 2023 $352.86M
Current Assets Q3 2024 · Sep 30, 2024 $308.35M
Current Assets Q3 2024 · Dec 31, 2023 $410.19M
Total Assets Q3 2024 · Sep 30, 2024 $558.51M
Total Assets Q3 2024 · Dec 31, 2023 $661.13M
Shares Diluted Q3 2024 · Sep 30, 2023 144.7M sh
Shares Diluted Q3 2024 · Sep 30, 2023 144.21M sh
Capex Q3 2024 · Sep 30, 2023 $9.4M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$129.39M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.35
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.08
Eps Basic Q3 2024 · Sep 30, 2023 −$0.35
Eps Basic Q3 2024 · Sep 30, 2023 −$1.08
Sga Expense Q3 2024 · Sep 30, 2023 $20.08M
Sga Expense Q3 2024 · Sep 30, 2023 $63.21M
Rd Expense Q3 2024 · Sep 30, 2023 $28.53M
Rd Expense Q3 2024 · Sep 30, 2023 $93.37M
Net Income Q3 2024 · Sep 30, 2023 −$50.3M
Net Income Q3 2024 · Sep 30, 2023 −$155.81M
Operating Income Q3 2024 · Sep 30, 2023 −$50.96M
Operating Income Q3 2024 · Sep 30, 2023 −$155.97M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $19.35M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $55.94M
Revenue Q3 2024 · Sep 30, 2023 $37.92M
Revenue Q3 2024 · Sep 30, 2023 $124.49M